Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed‐onset clinically significant cytomegalovirus infection after letermovir prophylaxis?
Having a matched unrelated donor, a CMV donor negative/recipient positive status, and a non-AML underlying disease were associated with delayed onset csCMVi. Prospective studies are needed to evaluate whether extended letermovir prophylaxis is beneficial for these patients.
Authors
- Maria A. Mendoza (ORCID: https://orcid.org/0000-0003-3822-0669)
- Raymund Rabe Razonable (ORCID: https://orcid.org/0000-0001-5248-0227)
- Matthew Thoendel (ORCID: https://orcid.org/0000-0002-5290-3362)
- Hassan B. Alkhateeb (ORCID: https://orcid.org/0000-0002-3609-8404)
- Eric Bhaimia (ORCID: https://orcid.org/0000-0001-7661-2976)
Institutions
- Rush University Medical Center (US)
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1111/tid.14377
- Citations
- 2
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- National Institutes of Health